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CASE REPORT
Leprosy in Denmark 1980–2010:  
a review of 15 cases
Huma Aftab1,2*, Susanne D. Nielsen1 and Ib C. Bygbjerg1,2
Abstract 
Background: Leprosy, caused by Mycobacterium leprae, is a chronic and progressive granulomatous disease affecting 
mainly the skin and the peripheral nervous system. If left unrecognized, the infection can lead to permanent nerve 
damage and disability. The clinical presentation depends on the immune response of the patient and can result in a 
wide spectrum of symptoms. Leprosy is a rare encounter in Scandinavia but remains endemic in some parts of the 
world, with some areas reporting an increasing incidence. We performed a retrospective record review of leprosy 
cases in Denmark from 1980 to 2010 with the purpose of presenting the most common geographical, demographic 
and clinical findings and to discuss the diagnostic and therapeutic challenges of patients with leprosy.
Case presentation: In total 15 cases were reviewed. The majority (87 %) of leprosy patients in Denmark were born in 
South- and Southeast Asia, and were presumed to have contracted the infection in their countries of origin. Patients 
were predominately young males (mean age: 28.6 years). Anaesthetic skin lesion with or without nerve enlargement 
were the most common clinical presentations (73 %). Immunological leprosy reactions were seen in 40 % of the cases. 
Diagnoses were based on clinical findings and skin biopsies. Treatment length varied but all patients received multid-
rug regimens.
Conclusion: Leprosy should be kept in mind when encountering patients with suspicious skin lesions originating 
from leprosy endemic areas or with history of travel or work in the tropics. Due to the long incubation period with 
symptoms presenting long after immigration or return, clinicians often do not have the diagnosis in mind. The wide 
spectrum of symptoms and immunological reactions further complicates the diagnostic process. Treatment of leprosy 
and the complicated immunological reactions, which frequently accompanies the infection, should be performed in 
collaboration with a specialist.
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Background
Comparative genomics indicates that leprosy origi-
nated in Eastern Africa or the Near East, and was spread 
by human migration to rest of the world. Leprosy was 
well-recognized in ancient India and China since 4000 
BC with the first known written reference to the dis-
ease 600 BC. Leprosy is believed to have arrived in Ire-
land through trade and commerce with the Far East and 
travelled to Scandinavia through the Vikings; however, 
some believe that the crusaders brought the disease to 
Europe from where it spread to the Americas [1]. Others 
believe that Alexander the Great’s Greek soldiers intro-
duced it to Europe [2]. By the 12th century leprosy had 
become a widespread disease in Denmark giving rise to 
numerous leprosy hospitals/centres, demanding a large 
number of victims and inflicting a great deal of socioeco-
nomic damage [3]. In Norway the disease raged well into 
the 19th century giving rise to the world’s first national 
patient registry. In 1873, driven by epidemiological stud-
ies, the causative agent of leprosy was discovered by the 
Norwegian physician Gerard Armauer Hansen [4], but 
not until a century later, in 1982, an efficient multidrug 
therapy (MDT) was recommended by the World Health 
Organisation (WHO) [5]. The global prevalence rate has 
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declined markedly following implementation of MDT. 
The WHO ‘elimination of leprosy’ goal is less than 1 per 
10,000 persons in a given population receiving MDT. 
Elimination of leprosy at global level was achieved by the 
year 2000. At present, leprosy is endemic in countries 
such as India, Indonesia and Brazil, and these countries 
account for the bulk of newly detected cases. Thus, in 
2013, a total of 180,618 cases were registered, and the 
prevalence rate was 0.32 in 10,000 worldwide [6]. How-
ever, no decline was recorded and a rising incidence in 
some countries indicate continuous transmission. Some 
attribute this to the intensified leprosy control and new 
case finding strategies in endemic regions and not an 
increasing incidence per se [7, 8].
The vast majority of infected individuals never develop 
clinically detectable symptoms and signs. Age and sex are 
important risk factors for developing leprosy: adolescents 
aged 10–19 and persons aged 30 or above are the most 
susceptible. Adult men are twice as likely to develop the 
infection as adult women [9]. Although, household con-
tacts of multibacillary (MB) cases have an increased risk 
of developing leprosy compared to the general popula-
tion, infection acquired outside the household and sub-
clinical infection is being recognized as an potential route 
of transmission, sustaining the high new detection rate of 
leprosy [10–13]; 90–95 % of spouses to infective leprosy 
patients did not acquire the infection in the pre-antibi-
otic era. Children of leprosy patients have an increased 
risk of acquiring the infection compared to the spouse, 
indicating that genetic similarity to the infected parent 
makes one more susceptible to the infection [14]. Even 
though some studies have shown an association between 
susceptibility to leprosy and certain genes/chromosomal 
regions, more studies are needed to fully understand the 
genetics of susceptibility to leprosy [15–17].
Today, in Scandinavia, as in most of Europe, leprosy 
remains non- autochthonous, brought to the region by 
immigrants from endemic areas, thus explaining its rar-
ity: In Denmark less than one case per year has been 
reported during the last 30 years, and the leprosy situa-
tion in Denmark was last reviewed more than 20-years-
ago [18].
The aim of our study was to give a brief overview of the 
history and of the current general knowledge on leprosy 
and conduct a retrospective review of leprosy cases from 
1980 to 2010 in Denmark with emphasis on clinical char-
acteristics and therapeutic challenges.
The causative agent
Leprosy is a chronic granulomatous infection caused 
by the intracellular acid fast bacilli Mycobacterium lep-
rae (M. leprae) and is most likely transmitted through 
droplets from the upper respiratory tract of bacilliferous 
patients. Although transmission through skin under con-
trolled laboratory conditions has been reported, infection 
through intact skin is not considered possible. The myco-
bacterium is difficult to study and has not successfully 
been cultured in  vitro but only in armadillos and foot-
pads of nude mice. The infection has low virulence and 
a mean incubation period of 4–5 years, but the incuba-
tion period may be much longer [19]. Incubation time for 
paucibacillary (PB) infections is assumed to be shorter 
than MB.
The bacilli exhibit tropism for histiocytes and Schwann 
cells, causing anaesthetic skin lesions, and sensorimotor 
function loss [20], and also for cooler parts of the body, 
such as eyebrows, earlobes and the nose.
Even though M. leprae has been isolated from several 
environmental and animal reservoirs including armadil-
los (10), most authors agree on humans being the main 
reservoir of infection [21].
The clinico‑pathological spectrum
The wide spectrum of clinical presentations reflects the 
complexity of the immune response towards the causa-
tive agent and is graded according to the widely used 
Ridley–Jopling scheme, which is primarily based on the 
immunological characteristics. Clinical and histo-patho-
logical characteristics are also considered, and delineated 
as two stable polar forms ranging from polar tuberculoid 
(TT) to polar lepromatous leprosy (LL), and in between 
the unstable borderline forms: borderline tuberculoid 
(BT), borderline leprosy (BB) and borderline leproma-
tous leprosy (BL). Thus, tuberculoid leprosy (T) refers to 
TT and BT while lepromatous leprosy forms (L) to BB, 
BL and LL. Borderline types are more likely to down- or 
upgrade through immunological reactions; type 1 reac-
tions [22]. Indeterminate leprosy, the earliest clinically 
detectable form of the disease is immunologically unsta-
ble. Most cases can be cured spontaneously, but some 
cases may go on to develop one of the determinate forms 
later. Leprosy may even present with nerve affection as 
the only symptom: pure neural leprosy.
The clinico-pathological features in leprosy are the 
result of a varying immune response. Thus, T by mount-
ing a strong cell mediated immune response restricts 
the infection to a single or few well demarcated, dry 
(anhydrosis) and scaly anaesthetic skin lesions (macules, 
plaques) with an elevated margin and central healing. 
The skin changes are often hypopigmented in dark skin 
and red/coppery coloured in lighter skin. Although early 
and significant nerve enlargement is common in T, and 
the most commonly affected nerves (most common one 
or few asymmetric nerve affections) are posterior tibial, 
ulnar, median, lateral popliteal, facial, and radial nerves 
(may also be affected in L), thickening of the cutaneous 
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nerves close to the skin lesion is an important diagnostic 
clue.
T lesions are dominated by CD4+ cells, histologically 
characterized by well-defined granulomas consisting 
of lymphocytes, epitheloid and giant cells and virtually 
no bacilli [23], i.e. paucibacillary. The cellular infiltra-
tion may extend up to the epidermal layer of the skin. 
The strong immune reaction in T is probably a result of 
switching towards a Th1 response. The Th1 type response 
in patients at the tuberculoid pole (TT and BT) results 
in abundance of interferon -γ (INF-γ), Tumor Necrosis 
Factor (TNF-α), interleukins (IL)-2 and IL-15 and a posi-
tive skin test (Lepromin test). At the opposite pole (L), 
the clinical picture reflects a weak cell mediated immune 
response leading to disseminated infection with multiple 
skin lesions often distributed symmetrically on the body. 
In contrast to T, L patients have multiple erythematous 
or slightly hypopigmented skin lesions (macules, papules 
and nodules), with poorly defined borders and smooth 
shiny surfaces which are not necessarily anaesthetic in 
early stages of the disease. Nerve enlargement and palsy 
also develop later as compared to T: most common as 
multiple symmetric nerve affection. Progressive L cases 
can develop a disseminated infiltration of the skin caus-
ing a waxy appearance and thickening of the skin, most 
prominent in the face, facies leonidae. L cases may dis-
play systemic symptoms affecting the eyes, testes, bones 
and liver.
L lesions are characterized by few T lymphocytes with 
a predominance of CD8+ cells, no granulomas, diffuse 
infiltration of undifferentiated ‘foamy’ macrophages and 
loads of bacilli, i.e. multibacillary. The epidermis stays 
intact until late stages of the disease. In contrast to the 
immune response seen in T, L lesions formed during the 
Th2 type response contain transcripts for IL-4, IL-5 and 
IL-10, are non-reactive to the Lepromin test and show 
high anti-M. leprae antibody titres which do not seem to 
convey any protection [24–26].
The unresponsiveness to M. leprae extracts in the Lep-
romin test in L may be explained by immune deviation 
(the above described Th1 and Th2 immune responses), 
deletion (varying Th0 cell responsiveness to M. leprae) 
and/or inhibition of T cell responses by regulatory T 
cells (Tregs) [27]. Some lepromatous patients are capa-
ble of mounting a Th1 response upon stimulation with 
cytokines such as IL-12 secreted by activated dendritic 
cells and stimulate naïve T cells which are present in T 
but not L lesions. This observation has led some to con-
clude that the Th2 immune status in L is reversible [28]. 
Findings from some studies though do not support the 
notion of immune deviation in leprosy [29] wherefore 
increasing interest in clarifying the role of Tregs in lep-
rosy has evolved. However, studies of Tregs in leprosy 
have found conflicting results as both increased and 
decreased frequency of Tregs in L patients have been 
found [30–32]. Thus, more investigations into the role of 
Tregs in leprosy are needed [33].
Diagnosing leprosy
According to WHO diagnostic criteria, a person with 
one of the two cardinal signs: (1) positive skin smear or 
(2) characteristic anaesthetic leprosy skin lesions with or 
without nerve thickening/enlargement with sensory or 
motor loss, is regarded as having leprosy. WHO recom-
mends a simpler classification scheme based on number 
of skin lesions and bacillary load in skin smears. This is 
often used to classify leprosy based on number of skin 
lesions alone, where Paucibacillary (PB) leprosy corre-
sponds with 1-5 skin lesions (indeterminate leprosy, TT 
and BT) and MB leprosy with >6 skin lesions (BB, BL and 
LL) [34].
However, a considerable amount of patients will be 
misclassified with risk of both over- and undertreatment. 
Therefore, if not used in the field for operational pur-
poses, experts recommend classifying patients according 
to the Ridley–Jopling scheme. Thus, whenever possible, 
a patient suspected of leprosy should undergo examina-
tion for the three cardinal signs of leprosy: (1) thorough 
inspection of the skin for leprosy lesions (morphology 
described above) and anaesthesia (light touch, pin prick 
and temperature) of such, (2) enlargement with or with-
out sensory or motor loss of most commonly affected 
peripheral nerves (predilection sites mentioned above), 
and (3) positive skin smear. A total of 3–6 skin smears 
should be performed from skin lesions and in L cases 
from cooler sites with a high probability of finding AFB 
(earlobes, the forehead, extensor surfaces of the forearms 
and knees). Skin smears are used to assess the bacillary 
load: the bacteriological index (BI) and the viability of 
the mycobacteria; the morphological index (MI). The BI 
indicating the bacterial load is expressed on a logarithmic 
scale from 1 +  (at least 1 bacillus in every 100 fields) to 
6 + (at least 1000 bacilli in every field). Leprosy patients 
with a BI < 2 are designated as PB while a BI > 2 as MB. 
Before WHO recommended the current operational 
method of counting skin lesions to classify a patient as PB 
or MB, a positive skin slit smear from any site designated 
the patient as MB. Skin slit smears show poor sensitivity 
(particularly in PB cases), but their high specificity is very 
useful for identifying MB, which is the most infectious.
Skin biopsies are usually performed when there is 
doubt about the diagnosis and remain the golden stand-
ard. Biopsies should be taken from an ‘active’ site i.e. red, 
enlarged and infiltrated. A modified Ziehl-Neelsen stain, 
such as the Wade Fite stain is preferable for the histologi-
cal diagnosis. The histopathological characteristics of T 
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and L are described above. According to WHO, only lep-
rosy bacilli which appear as solid acid fast rods are viable 
while dead leprosy bacilli stain irregularly; this can aid in 
assessing the treatment effect.
The Lepromin test is analogous to the tuberculin test 
used in tuberculosis. It relies on the host’s ability to 
mount a delayed hypersensitivity reaction after an intra-
dermal injection of M. leprae antigens. The Lepromin 
test has low sensitivity and specificity, and a long waiting 
period of 3 weeks before a reaction can be observed after 
injection; therefore the test is rarely used. It has no diag-
nostic value, and was previously used to classify leprosy 
patients in tuberculoid when positive, and in leproma-
tous when negative.
Serological tests are under development but are not 
used routinely due to their low sensitivity in patients at 
the tuberculoid pole, and have shown false positive reac-
tions in non-leprosy patients [35]. Some studies indicate 
that antibodies specific M. leprae antigens may be useful 
for detection of early disease in house hold contacts and 
for monitoring treatment efficacy [36, 37].
PCR for M. leprae is sensitive and specific but not 
widely applied due to cost. Its use until now has been 
for epidemiological research purposes. In endemic areas 
it has a promising role for detection of early leprosy, PB 
cases with a low bacillary load and relapse [38–40].
Treatment
The WHO MDT for leprosy has proven to be highly 
effective and should be the first choice for all patients. 
Patients with up to five skin lesions and/or no bacilli (PB) 
are treated for 6 months with daily dapsone and monthly 
rifampicin, while multibacillary (MB) cases with more 
than six skin lesions and abundant bacilli should undergo 
a 12  months course of daily dapsone and clofazimine 
supplemented by monthly rifampicin and clofazimine 
[41]. Skin lesions in MB patients with a high BI may clear 
more slowly and have a high BI at the end of treatment 
compared to MB patients with a lower BI; if such patients 
do not show improvement after completion of 12 months 
of MDT, WHO recommends an additional 12 months of 
MDT.
Severe haemolysis can follow dapsone treatment in 
patients with Glucose-6-Phosphate Dehydrogenase 
(G6PD) deficiency. Dapsone should therefore be avoided 
in these patients. An adverse effect of clofazimine which 
doctors should be aware of, since it can lead to poor com-
pliance, is reddish discoloration of the skin, conjunctivae 
and body excretions such as sputum and urine.
Second line agents, ofloxacin and minocycline can be 
used in a single dose regimen for PB cases; Rifampicin-
Ofloxacin-Minocycline, ‘ROM,’ for patients with a sin-
gle leprosy skin lesion. This regimen was introduced by 
WHO in 1998 and should only be administered after 
careful examination of the skin making sure the patient 
only has one lesion and no nerve involvement. Since 
ROM has proven to be less effective than MDT for treat-
ment of PB cases with more than one skin lesion, it is 
currently not recommended for PB cases presenting with 
2–5 skin lesions [42].
Leprosy reactions
Around 30  % of borderline cases experience type 1 
[43] reactions resulting in an upgrading of the cellu-
lar immune response, shifting the patients towards the 
tuberculoid pole and a Th1 response. Leprosy type 1 
reactions are type IV delayed hypersensitivity immune 
reactions. The reactions are most commonly observed 
at initiation of therapy or during the puerperium. How-
ever, when the immune system fails to contain the infec-
tion a downgrading towards the lepromatous pole is 
taking place. Distinction between up- and downgrad-
ing may be difficult, and may require histo-pathological 
examination, although downgrading is usually observed 
prior to initiation of leprosy treatment, whereas upgrad-
ing, often occurs as a response to treatment. Type 1 up- 
and downgrading reactions cause acute inflammation of 
existing skin (oedema and ulceration) and nerve (motor-
sensory loss) disease, new lesions and nerve involve-
ment can also appear. Prompt diagnosis and treatment 
is of utmost importance due to the risk of permanent 
nerve damage. Patients should undergo thorough exam-
ination of nerves most commonly affected (as described 
earlier) and followed closely. Prednisolone starting 
at 30–40  mg tapered to 5  mg over 5–6  months under 
close observation of nerve function is generally recom-
mended for type 1 reactions; there is however, currently 
no consensus on dosage and treatment duration [43]. 
Results are awaited from controlled trials looking into 
different treatment regimens with prednisolone for lep-
rosy patients with nerve impairment, and the effect of 
prednisolone prophylaxis for subclinical nerve function 
impairment [44].
Type 2 reactions, erythema nodosum leprosum (ENL) 
are mainly seen in BL and LL patients of whom 50 % (the 
50 % refers to the subpolar LL group which is immuno-
logically unstable compared to the LL polar form) are at 
risk of experiencing this complication. ENL is a type III 
immune response brought about by the inflammatory 
reaction towards immune-complexes. The immune-com-
plexes deposited in various organ systems cause fever, 
erythematous painful nodules, uveitis, neuritis, arthritis 
and orchitis [45]. ENL lesions are characterized by heavy 
neutrophil infiltration and high levels of TNF-α. The 
immunological mechanisms underlying the leprosy reac-
tions are not fully understood [46].
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Severe ENL can be life threatening and require pro-
longed immunosuppressive treatment. WHO rec-
ommend corticosteroids 1  mg/Kg body weight for 
12 weeks. In case of severe ENL not responding to cor-
ticosteroid, clofazimine a corticosteroid sparing agents 
can be used; according to WHO guidelines clofazi-
mine should be started at 100 mg, three times a day for 
maximum 12 weeks, where after it should be tapered to 
100 mg twice a day for 12 weeks and then 100 mg once 
a day for 12–24  weeks. Clofazimine is more effective 
than thalidomide for prevention of ENL recurrences. 
Thalidomide in doses of 100–400  mg/day have shown 
to be effective in controlling the reaction, but more and 
larger trials are needed to prove its efficacy [47], and 
due to its teratogenic side effects, WHO does not rec-
ommend its use for the treatment of ENL in women of 
childbearing age [48]. Despite this: thalidomide is by 
many practitioners considered to be the most effective 
drug against ENL. Pentoxifylline is less effective than 
thalidomide, but has shown to be effective in alleviating 
ENL symptoms, and could be used as an alternative to 
thalidomide against ENL when thalidomide is contrain-
dicated [49].
The time frame is important when distinguishing 
between relapse and leprosy reactions: New elements or 
nerve affection appearing less than 3  years after a suc-
cessful course of MDT is more likely to be a reaction. 
However, the final diagnosis will depend on presence or 
not of bacilli. According to WHO a relapse in a MB case 
is defined as “multiplication of M. leprae, suspected by 
the marked increase (at least 2+ over the previous value) 
in the BI at any single site, usually with evidence of clini-
cal deterioration”. To distinguish between relapse and 
reversal reactions in PB cases a trial of prednisolone is 
recommended; improvement within 4 weeks favours the 
diagnosis of a reversal reaction.
Although co-infection with HIV does not seem to shift 
the patients towards the L pole, some studies indicate 
an increased incidence of type 1 reactions in patients 
receiving anti-retroviral treatment, probably as part of an 
immune reconstitution syndrome [50, 51].
Methods
Leprosy is a mandatory notifiable disease in Denmark. 
Based on social security numbers, and retrieved from the 
national surveillance service database at Statens Serum 
Institut (SSI) leprosy cases reported in the period Janu-
ary, 1980 to December, 2010 were reviewed. Additionally, 
we searched the patient register at University Hospital of 
Copenhagen, Rigshospitalet which is the main referral 
hospital for tropical diseases in Denmark. For elabora-
tion on medical history, clinical presentation, diagnostic 
procedures and treatment, medical records, photographs 
and letters from these and other notifying hospitals were 
collected.
Permission to obtain information about leprosy cases 
was granted by the Danish National Board of Health 
(Additional file 1).
Case presentation
From 1980 to 2010, 17 cases of leprosy were reported to 
SSI and five additional cases were identified in the Rig-
shospitalet patient register. Only 14 of 22 journals were 
available. One of the cases had been suspected for lep-
rosy, but this was never confirmed. This left us with 13 
available medical records of confirmed cases. For two 
patients, information was collected from letters, pho-
tographs and personal correspondence with the attend-
ing physician. Thus, in total, information on 15 leprosy 
patients was reviewed.
The available data were reviewed with focus on demo-
graphic data, clinical findings, diagnostic procedures and 
treatment. The results of these findings are summarized 
in Table 1.
Leprosy was predominately imported to Denmark from 
South- and Southeast Asia (87  %), in particular India, 
The Philippines and Cambodia, all areas where leprosy is 
endemic; only two cases originated from African coun-
tries. Age of patients ranged from 5 to 74 years, and 11 of 
15 patients (73 %) debuted in their second or third dec-
ade of life. The youngest patient (5-years-old) was a girl 
who had most probably contracted the infection from her 
father, who had been treated for leprosy in Nepal.
Three patients (20 %) recalled exposure to leprosy. Five 
patients (33 %) were diagnosed and had also undergone 
treatment for leprosy before migrating to Denmark, 
while one patient (7 %) was defined as a relapse after con-
sulting a leprologist in London.
Diagnosis was based on travel history, clinical and path-
ological findings. Most patients were classified according 
to the Ripley and Jopling scheme. Among the 15 patients 
53  % were classified as borderline leprosy types evenly 
distributed along the spectrum, whilst 33 and 7  % were 
classified as TT and LL respectively. Duration of symp-
toms varied from 3 weeks to 8 years, but it was only pos-
sible to deduce the length of delay in diagnosis from a few 
medical records since the date of the first contact with a 
medical professional was rarely mentioned. For the few 
for whom the dates were available, the time period from 
contact with a doctor to suspicion of leprosy was only a 
few weeks.
Common clinical features were hypopigmentation, 
slightly dark reddish/brown skin lesions (macules, nod-
ules and plaques), hyposensitivity/anaesthesia of skin 
lesions, nerve enlargement and palsy, in particular the 
ulnar and peroneal nerves. Approximately 73 % of cases 
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presented with the two cardinal signs: anaesthetic skin 
lesions and peripheral nerve thickening. The most com-
mon symptom bringing the patient in contact with health 
authorities was skin changes mimicking conditions such 
as sarcoidosis and pityriasis versicolor. Initially, two lep-
rosy cases (13  %) were, based on the histo-pathological 
finding of granulomatous skin changes, mistaken for 
sarcoidosis.
According to the records available, slit skin smears 
were performed in seven of the 15 patients (47  %), and 
the results recorded in six (40  %). The patients from 
whom skin smears were not obtained were all classified 
as TT/BT cases. Skin biopsies were obtained from all 
patients, often on the suspicion of other dermatologi-
cal disease (Fig. 1). Bacilli were visualized in six of the 15 
(40  %) skin biopsies, of which five were borderline lep-
rosy types (BT, BB and BL) while one was a LL patient. 
Non-necrotizing granulomatous changes were found in 
nine biopsies (60 %). The Wade Fite stain was used on all 
biopsies but one. Histopathological description of biop-
sies from patients with TT was only available for the one 
patient who experienced a relapse. This showed hyper-
plasia of the epidermis, perivascular inflammation con-
sisting of lymphohistiocytes, granulocytes and plasma 
cells and no granulomas. Biopsies from patients in the 
BT/BB spectrum showed epitheloid cells granulomas, 
giant cells and an unaffected epidermal zone, while BB/
BL was characterized by a more diffuse infiltration with 
or without lymphocytes, no giant cells and in some cases, 
‘foamy’ macrophages and AFB. Confluent infiltrates of 
histiocytes with neutrophile granulocytes and loads of 
AFB was the main finding in the LL relapse patient. PCR 
for detection of M. leprae was not performed in any of 
the 15 cases.
Four of the 15 patients (27  %) experienced a type 1 
reaction of which two were classified as borderline lep-
romatous and diagnosed as downgrading reactions 
before initiation of leprosy treatment while the remain-
ing presented with type 1 reaction symptoms shortly 
after initiation of leprosy treatment. The patients with 
downgrading type 1 reactions displayed the following 
symptoms: appearance of new anaesthetic skin elements 
and signs of increased inflammation of the existing ones. 
Both patients were feverish, one of them with increased 
C- reactive protein and neutrocytosis. Arthralgia and 
dactylitis were also present in both cases, while only one 
of them developed nerve palsy (drop foot). One patient 
experienced a type 1 reaction shortly after treatment 
initiation in Cameroun, before arriving in Denmark; the 
only symptom mentioned in the medical records regard-
ing this was nerve palsy (peroneus paralysis). Half of the 
patients experiencing a type 1 reaction were treated with 
corticosteroids.
The patients reacting with ENL (13  %) were BL/
LL patients experiencing fever, universal lymphad-
enitis, flaring of skin elements in the form of inflamed 
noduli on the upper extremities. One had enlargement 
of the ulnar and auriuclaris magnus nerves, which was 
Table 1 Summary of  demographic and  clinical features 
of  leprosy patients in  Denmark recorded from  1980 
to 2010
Variable Leprosy patients 
(N = 15), n (%)
Age (years)
 Range 5–74
 Median 23
Gender
 Male 9 (60)
 Female 6 (40)
Country of origin
 Philippines 3 (20)
 Cambodia 3 (20)
 India 3 (20)
 Pakistan 1 (7)
 Cameroon 1 (7)
 Tanzania 1 (7)
 Thailand 1 (7)
 Sri Lanka 2 (13)
Duration of stay in Denmark (years)
 Range 0–20
 Median 0
  0–5 11 (73)
  ≤6–10 0
  ≤11–15 0
  ≤16–20 1 (7)
  Unknown 3 (20)
Duration of clinical presentation (weeks)
 Range 3–384
 Median 36
Classification
 Tuberculoid leprosy (TT) 5 (33)
 Borderline tuberculoid leprosy (BT)/Borderline lep-
rosy (BB)/Borderline lepromatous leprosy (BL)
8 (53)
 Lepromatous leprosy (LL) 1 (7)
 Indeterminate leprosy 1 (7)
Reactions
 Type 1 4 (27)
 Type 2 2 (13)
Histopathological findings
 Skin smears positive for bacilli (7 patients had skin 
smears performed)
3 (43)
 Granulomas in biopsies 9 (60)
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treated with a 1 week thalidomide course while the other 
received prednisolone due to systemic symptoms with 
haematuria.
Most common complication/sequelae were decreased 
sensibility, particularly on the peripheral extremi-
ties, ulcers and secondary infections due to neuropa-
thy, as well as keratosis and atrophy of fingers and toes. 
These patients were referred to an orthopaedist and/
or orthopaedic surgeon for evaluation and treatment. 
Two patients had undergone amputation of fingers/toes, 
in total grade 2 disability (G2D) was recorded for three 
patients (20  %). One of three patients with G2D had 
the amputations done in Cameroun, while another had 
received several years of leprosy treatment in Thailand, 
and had been living with G2D for some time when a new 
reaction (ENL) brought him to a physician in Denmark; 
bringing G2D to 6 % in our patient sample.
Some patients experienced improvement of their sen-
sory disturbances during treatment but none had com-
plete remission.
Skin lesion with findings of granulomatous changes in 
skin biopsies often led to the suspicion of sarcoidosis. 
Other differential diagnoses mentioned were mostly der-
matological: acne, pityriasis versicolor, erythema multi-
forme and Sweets syndrome.
All patients, diagnosed with leprosy after 1982, when 
WHO launched the use of MDT, received this regi-
men. Duration of treatment varied and was not for all 
cases in accordance with WHO recommendations. 
Some received prolonged MDT (up to 12  years) due to 
continued presence of bacilli in skin samples, despite 
clinical improvement.
Conclusion
Leprosy remains a sporadic disease imported to Den-
mark. With less than one case detected per year it 
remains difficult for doctors in non-endemic countries 
to recognize or even to think of leprosy, which may lead 
to delay of diagnosis and treatment [52]. Delayed diagno-
sis may lead to blindness, permanent nerve-damage and 
other disabilities. Even though anaesthesia of skin lesions 
is an important distinguishing feature it is often not rec-
ognized by the patient.
According to some leprologists there is a predomi-
nance of male leprosy patients after puberty, this was also 
the case in our patient sample. Skin smears were not per-
formed in 53 % of the patients and although these were 
classified as TT/BT cases not expected to be skin smear 
positive, skin smears should be performed in all patients 
suspected for leprosy. Only one patient could recall close 
contact to an infectious leprosy patient in the household.
Skin biopsies, perhaps because of diagnostic uncer-
tainty, were performed in all patients. Demonstration of 
acid fast bacilli was not possible in seven of the 15 (60 %) 
skin biopsies; therefore exposure, travel history and clini-
cal presentation were essential to supplement histology. 
The more sensitive PCR for M. leprae could have proven 
helpful in these cases [53].
Classification of the disease is important for several 
reasons: borderline patients are unstable and at risk 
Fig. 1 a 22-year-old Filipino woman with leprosy initially suspected for sarcoidosis. The patient was designated as a case of BT/BB with a type 1 
reaction (a). WADE FITE special stain of skin biopsy showing the acid fast M. leprae bacilli. b Slightly elevated, scaly and light coppery coloured plaques 
on the right leg. Similar lesions were present universally
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of experiencing type 1 reaction that can lead to serious 
nerve damage, while lepromatous and borderline lepro-
matous leprosy is associated with type 2 reactions which 
often are complicated by systemic effects. Both these 
conditions require corticosteroids and close monitoring 
of the clinical course due to the tendency to recur caus-
ing further damage [54, 55]. Another aspect making clas-
sification important is when choosing treatment regimen: 
cf. WHO’s recommendations which are only 6  months 
for paucibacillary against 12  months for multibacillary 
leprosy. Skin samples can be positive for non-viable-
bacilli years after completion of MDT, and this is not an 
indication for prolongation of treatment. Unfortunately, 
viability may be difficult to determine, unless the bacilli 
are looking disintegrated/discoloured at microscopy. 
There are no standard international guidelines for how 
often and how long after completion of MDT a patient 
should be examined with skin smears. It is also unclear 
how long a patient should be followed after ending treat-
ment. WHO recommends skin smears at the start of 
treatment and if relapse/deterioration is suspected. Lead-
ing leprologists prefer to discharge patients if they dis-
play no complications and are smear negative, except MB 
patients, who are followed for 2 years after completion of 
MDT, whilst patients with permanent eye and/or nerve 
damage are followed lifelong.
Due to the long incubation period, the diagnosis 
should be kept in mind when encountering patients from 
endemic areas displaying dermatological or neurological 
symptoms even years after immigration. Special atten-
tion and care should be given to detection and treatment 
of complications, in particular to those with neuropathy, 
which can be lasting. Anaesthetic skin lesions, which 
were the most common clinical finding in our review, 
should lead to a high suspicion of leprosy.
Consent
The Danish National Board of Health granted permis-
sion to publish this case report. Written informed con-
sent was obtained from the patient for publication of case 
reports and any accompanying images.
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